Skip to Content
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees
  • Market Value — as of March 29, 2018 ($M)

Last year marked the end of an era for Pfizer. As the company’s patent exclusivity expired for Viagra, its blockbuster erectile dysfunction drug, the pharmaceutical giant has struggled to discover its next big hit. In January, Pfizer discontinued its research into treatments for Alzheimer’s and Parkinson’s. And after long resisting calls to split itself up, the company is now mulling whether to sell its consumer healthcare business to suitors such as Procter & Gamble. Meanwhile Pfizer, which acquired biosimilars maker Hospira in 2015, is still working to address that company’s manufacturing issues, which have led to drug shortages.

Company Info

Ian C. Read
CEO Title
Chairman & Chief Executive Officer
Health Care
HQ Location
New York City
Years on Fortune 500 List24
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Pfizer Rank History


Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$52,546.00-0.5%
Profits ($M)$21,308.00195.3%
Assets ($M)$171,797.00-
Total Stockholder Equity ($M)$71,308.00-
Market Value — as of March 29, 2018 ($M)$211,115.30-

Profit Ratios

Profit as % of Revenues40.6%
Profits as % of Assets12.4%
Profits as % of Stockholder Equity29.9%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)3.52
EPS % Change (from 2016)200.9%
EPS % Change (5 year annual rate)12.7%
EPS % Change (10 year annual rate)11.6%

Total Return

Total Return to Investors (2017)15.7%
Total Return to Investors (5 year, annualized)11.4%
Total Return to Investors (10 year, annualized)9.3%